Clinical experience with vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors is rapidly increasing, and some compounds have already been approved for regular anticancer treatment. Apart from their activity, much attention has been focussed on the clinical toxicity profile of these compounds. This review describes the most frequently occurring side-effects of both antibodies and tyrosine kinase inhibitors and discusses some of the underlying mechanisms. Some practical guidelines for treatment of the side-effects are given.

, , , , ,
doi.org/10.1016/j.ejca.2006.09.015, hdl.handle.net/1765/66204
European Journal of Cancer
Erasmus MC: University Medical Center Rotterdam

Eskens, F.A.L.M, & Verweij, J. (2006). The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review. European Journal of Cancer, 42(18), 3127–3139. doi:10.1016/j.ejca.2006.09.015